Nektar Therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. Nektar also partners with the top biopharmaceutical companies to bring new products to market. To date, Nektar''s technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.
Nektar''s proprietary Advanced Polymer Conjugate Technology platform allows for a custom approach that capitalizes on the properties of polymer medicinal chemistry and an understanding of both a drug''s characteristics and the body''s mechanisms.
Our scientists identify specific drug molecules, both large and small, that with customized chemical modification using uniquely-designed polymers can be enabled or made more efficacious. With our proprietary conjugate approaches, suboptimal drugs can be designed to dial in desired therapeutic properties and create an optimized and potentially superior therapeutic.